Akt1 and Akt2-IN-1

• CAT Number: I005347
• CAS Number: 893422-47-4
• Molecular Formula: C33H29N7O
• Molecular Weight: 539.63
• Purity: ≥95%
• Target: Akt
• Solubility: DMSO: ≥ 35 mg/mL
• Storage: Store at -20°C
• IC50: 3.5 nM (Akt1), 42 nM (Akt2)
• IUPAC Name: 3-phenyl-2-[4-[[4-(3-pyridin-2-yl-1H-1,2,4-triazol-5-yl)piperidin-1-yl]methyl]phenyl]-6H-1,6-naphthyridin-5-one
• InChI: InChI=1S/C33H29N7O/c41-33-27-20-26(23-6-2-1-3-7-23)30(36-28(27)13-17-35-33)24-11-9-22(10-12-24)21-40-18-14-25(15-19-40)31-37-32(39-38-31)29-8-4-5-16-34-29/h1-13,16-17,20,25H,14-15,18-19,21H2,(H,35,41)(H,37,38,39)
• InChIKey: BTUWHHFNOHVCMQ-UHFFFAOYSA-N
• SMILES: C1CN(CCC1C2=NC(=NN2)C3=CC=CC=N3)CC4=CC=C(C=C4)C5=C(C=C6C(=N5)C=CNC6=O)C7=CC=CC=C7

Akt1 and Akt2-IN-1(CAT: I005347) is a potent allosteric inhibitor targeting both Akt1 (IC₅₀ = 3.5 nM) and Akt2 (IC₅₀ = 42 nM) with balanced activity. By binding to the allosteric site, it disrupts Akt activation and phosphorylation, effectively blocking downstream signaling pathways involved in cell survival, proliferation, and metabolism. This compound is particularly valuable in cancer research for exploring the role of the PI3K/Akt pathway in tumorigenesis and drug resistance. Its specificity and potency make it an essential tool for studying Akt-driven cellular processes and for the development of targeted therapies for cancers and metabolic disorders associated with dysregulated Akt signaling.